Advertisement
Organisation › Details
Rigenerand S.r.l.
Rigenerand SRL is a biotech company that both develops and manufactures medicinal products for cell therapy applications, primarily for regenerative medicine and oncology and 3D bioreactors as alternative to animal testing for pre-clinical investigations. Rigenerand operates through three divisions: 1) a proprietary pipeline, developing and GMP manufacturing of cell and gene therapies for cancer treatment, 2) a CDMO division, providing GMP support for scale-up of cell based medicinal products for clinical and commercial purposes within fully equipped Grade A/B cleanrooms, and 3) a division developing 3D technologies for cell culture, developing and manufacturing 3D solutions for R&D diagnostics and pre-clinical purposes (VITVO(R)). Rigenerand is developing RR001, a proprietary ATMP gene therapy medicinal product for the treatment of pancreatic ductal adenocarcinoma (PDAC). RR001 has been granted an Orphan Drug Designation (ODD) by US-FDA and from the European Medicine Agency. The Clinical trial is expected to start in Q1 2021. Rigenerand is headquartered in Medolla, Modena, Italy, with more than 1,200 square metres of offices, R&D and quality control laboratories and a cell factory of 450 square metres of sterile cleanroom (EuGMP Grade-B) with BSL2/BSL3 suites for cell and gene therapies manufacturing. It combines leaders and academics from biopharma and medical device manufacturing sectors. *
Start | 2009-01-01 established (s-off) | |
End | 2022-07-05 renamed | |
Group | Evotec (Group) | |
Today | Evotec (Modena) S.r.l. | |
Predecessor | University of Modena | |
Successor | Evotec (Modena) S.r.l. | |
Industry | cell therapy | |
Industry 2 | gene therapy | |
Person | Mari, Giorgio (Rigenerand 202006 CEO) | |
Person 2 | Dominici, Massimo (Univ Modena 202006 Professor + Scientific Founder of Rigenerand) | |
Region | Medolla (MO) | |
Country | Italy | |
Street | 4 Via Maestri del Lavoro | |
City | 41036 Medolla (MO) | |
Tel | +39-0535-1876172 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Rigenerand S.r.l.. (6/2/20). "Press Release: Rigenerand Receives Regulatory Approval for Gene Therapy Production". Modena. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Evotec (Group)
- [1] Evotec SE. (1/4/24). "Press Release: Evotec and Owkin Enter an A.I.-powered Strategic Partnership to Accelerate Therapeutics Pipeline in Oncology and I&I". Hamburg & Paris....
- [2] Evotec SE. (1/3/24). "Press Release: Evotec Announces CEO Transition. Dr. Werner Lanthaler to Step Down as CEO". Hamburg....
- [3] Evotec SE. (10/5/23). "Press Release: Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners Launch '65LAB'". Hamburg & Singapore....
- [4] Evotec SE. (7/11/23). "Press Release: Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership". Hamburg....
- [5] Evotec SE. (5/12/23). "Press Release: Evotec Publishes Annual Report 2022 and Quarterly Statement for Q1 2023". Hamburg....
- [6] Evotec SE. (5/9/23). "Press Release: Just – Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing". Hamburg & Seattle, WA....
- [7] Evotec SE. (2/10/23). "Press Release: Evotec Receives € 150 m Loan from European Investment Bank". Hamburg & Toulouse....
- [8] Evotec SE. (2/7/23). "Press Release: Laetitia Rouxel to Succeed Enno Spillner as Chief Financial Officer". Hamburg....
- [9] Formycon AG. (2/7/23). "Press Release: Enno Spillner Appointed Chief Financial Officer (CFO) of Formycon AG". Munich....
- [10] Evotec SE. (1/26/23). "Press Release: Evotec Announces Agreement with Janssen to Develop Immune-based Therapies". Hamburg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top